Krishna R. Kalari, Ph.D., focuses on the development of novel systems pharmacology approaches to investigate cancer genomics. She is actively involved in the development of algorithms and application of computational methods to identify pathways associated with cancer and variation to drug response phenotypes.
- Developing novel computational approaches to study genomic medicine
- Actively involved in developing a computational system to integrate multiple genomic features (such as expression, copy number, splicing variants, mutations and methylation) obtained from tumor and germline genomes to pharmacogenomic variation in response to antineoplastic drugs
- Applying machine learning methods to identify druggable candidates for passenger and driver mutation pathways to treat breast cancer
- Integrating computational genomics with pharmacokinetic or pharmacodynamic models
Significance to patient care
The computational methods developed will help researchers and clinicians interpret data to determine functionally relevant loci associated with disease and drug response phenotypes.
- Member, American Association for Cancer Research, 2010-present
- Member, International Society for Computational Biology, 2004-present
- Eveleigh Family Career Development Award, Mayo Clinic, 2011-2013
- International Society for Computational Biology Award, 2008 and 2011